Autolus Secures FDA RMAT Status for Obe-Cel in Lupus Treatment

Autolus Therapeutics secured Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration for its lead CAR T cell therapy candidate, obe-cel, targeting systemic lupus erythematosus and lupus nephritis as clinical trials advance.

The regulatory designation provides an accelerated review framework intended to expedite the development of promising cell therapies for serious conditions. Shares of Autolus Therapeutics (AUTL) traded down 3.79% at $2.03, compared to a previous close of $2.11, as of September 9, 2026, according to Finnhub market data.

"SLE and LN are serious autoimmune diseases with a critical unmet need for new therapeutic options, particularly for patients with severe refractory disease," said Dr. Matthias Will, Chief Development Officer of Autolus, in a company press release. "We are grateful to have received the RMAT designation for obe-cel based on the Phase 1b data reported from the CARLYSLE trial and believe it provides an important framework to facilitate efficient development within the LUMINA trial."

Clinical Trial Timeline and Milestones

The FDA granted the RMAT status following early clinical findings generated during the Phase 1b portion of the CARLYSLE trial. Autolus submitted the next scheduled data update from the CARLYSLE study for presentation at the American College of Rheumatology Annual Meeting, which is slated for the fourth quarter of 2026.

Simultaneously, the company is advancing its pivotal Phase 2 trial, known as LUMINA, which evaluates obe-cel in patients diagnosed with refractory lupus nephritis. The study is actively enrolling participants across five countries, with management anticipating initial data readouts in 2028.

Understanding the RMAT Framework

Established under the 21st Century Cures Act, the FDA's Regenerative Medicine Advanced Therapy designation is designed to accelerate the development and review of regenerative medicine products that intend to treat, modify, reverse, or cure serious or life-threatening conditions. Qualifying therapies receive benefits similar to breakthrough therapy designation, including early interactions with regulators, potential priority review upon biologic license application submission, and efficient pathways for clinical trial design.

For biopharmaceutical developers targeting complex autoimmune diseases, achieving RMAT status reduces regulatory friction during mid-stage clinical scaling. Systemic lupus erythematosus and lupus nephritis represent chronic inflammatory conditions where conventional immunosuppressive treatments frequently fail in severe cases, creating significant demand for cell-based interventions that can reset pathogenic immune responses.